Lesson Learned from COVID-19 Critically Ill Patients

Herawati, Fauna and Yulia, Rika and Kantono, Kevin and Wijono, Heru (2023) Lesson Learned from COVID-19 Critically Ill Patients. In: 2nd International Conference on Infectious and Tropical Diseases (ICITD) 2023, November 18-19, 2023, ASEEC Tower Universitas Airlangga.

[thumbnail of Lesson Learned.pdf] PDF
Lesson Learned.pdf

Download (596kB)
[thumbnail of LOA ICITD 2023-Fauna Herawati-OP03.pdf] PDF
LOA ICITD 2023-Fauna Herawati-OP03.pdf

Download (407kB)
Official URL / DOI: https://icitd.itd.unair.ac.id/web/


Background: Pandemics such as Spanish flu, SARS, and COVID-19 have occurred and are likely to happen in the future. This study evaluates critically ill patient characteristics and their medications. Methods: The study collected medical records of severe to critically ill COVID patients in the ICU from five hospitals. Data gathered included gender, age, severity, length of stay, and comorbidities. Data on drug use was collected, including type, dose, frequency, and duration were analyzed descriptively. The study investigated the effectiveness of antibiotics and antivirals using a mixed-logit regression model at a significance level of 5%. Results: Among 244 COVID-19 patients, 181 were over 45 years old, and 124 were critically ill. Antibiotics, antivirals, and steroids were the most drugs used for COVID-19 treatment. Some commonly used drugs include levofloxacin, moxifloxacin, azithromycin, remdesivir, mefenamic acid, ceftazidime, dexamethasone, and favipiravir. Meropenem, a broad-spectrum antibiotic, was also used as a treatment for COVID-19 patients (0.7-41.2 DDD per 100 bed days). Dexamethasone increases the likelihood of patient recovery with an odds ratio of 3.95 [1.81-8.68]. Conclusions: Antibiotic overuse contributes to resistance despite limited evidence. Remdesivir is preferred over Favipiravir for severe COVID-19. Studies show mixed results for antiviral benefits in patient outcomes. It is necessary to conduct further research on an appropriate therapy, develop neither new drug nor repurposing drug, for the flu virus.

Item Type: Conference or Workshop Item (Paper)
Uncontrolled Keywords: COVID, Drug Use Study, hospital
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Pharmacy
Depositing User: Ester Sri W. 196039
Date Deposited: 21 Nov 2023 06:32
Last Modified: 21 Nov 2023 06:34
URI: http://repository.ubaya.ac.id/id/eprint/45375

Actions (login required)

View Item View Item